GYRE
Gyre Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$5.88-2.81%
Price as of Jul 20, 2026
GYRE profitability
Gyre Therapeutics, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 95.1%
- EBITDA margin
- 2.7%
- EBIT margin
- -0.1%
- Net margin
- -5.4%
- Free cash flow margin
- 2.6%
Returns
- Return on equity
- -6.2%
- Return on assets
- -3.9%
- Return on invested capital
- -0.1%
- Asset turnover
- 0.71x
Cash efficiency
- Cash from operations
- $4.3M
- Cash per share
- $0.55
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.